XML 68 R57.htm IDEA: XBRL DOCUMENT v3.21.2
Note 12 - Segment Information - Operating Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Total revenues $ 35,840 $ 31,860 $ 70,760 $ 61,801
Gross profit (loss) 23,140 21,285 45,351 41,625
Operating expenses 18,939 16,815 38,027 33,585
Operating income 4,201 4,470 7,324 8,040
Nonoperating (income) expense, net (342) 2,086 1,363 4,902
Earnings before income taxes 4,543 2,384 5,961 3,138
Operating Segments [Member]        
Total revenues [1] 35,840 31,860 70,760 61,801
Gross profit (loss) 23,215 21,202 45,447 41,561
Operating Segments [Member] | Sterilization and Disinfection Control [Member]        
Total revenues [1] 14,033 11,552 29,183 24,619
Gross profit (loss) 10,486 8,770 21,914 18,790
Operating Segments [Member] | Biopharmaceutical Development [Member]        
Total revenues [1] 10,555 9,131 19,432 15,080
Gross profit (loss) 6,601 6,212 11,293 10,678
Operating Segments [Member] | Instruments [Member]        
Total revenues [1] 6,970 7,558 14,532 15,238
Gross profit (loss) 4,112 4,852 8,772 9,541
Operating Segments [Member] | Continuous Monitoring [Member]        
Total revenues [1] 4,282 3,619 7,613 6,864
Gross profit (loss) 2,016 1,368 3,468 2,552
Corporate, Non-Segment [Member]        
Gross profit (loss) [2] $ (75) $ 83 $ (96) $ 64
[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
[2] Non-reportable operating segments and unallocated corporate expenses are reported within Corporate and Other.